November 2012 Blog Posts (19)

Study Shows New Real-Time Electronic Reporting Dramatically Improves Adherence to Quality Standards for Breast and Colon Cancers

A large study reports that a new real-time performance tracking system, which monitors adherence to five National Quality Forum endorsed quality care metrics for breast and colon cancer, significantly improved quality standard adherence rates over a four-year period in a group of 64 cancer centers participating in the Rapid Quality Reporting System or RQRS “beta test.” Use of the system also reduced reported…


Added by Peter Hofland, PhD on November 27, 2012 at 6:30pm — No Comments

Voluntary Self-Assessment Helps Oncology Practices to Improved Quality of Patient Care

An analysis of self-reported data from outpatient oncology practices participating in the American Society of Clinical Oncology’s (ASCO) Quality Oncology Practice Initiative (QOPI®) showed marked improvements in overall quality of care delivered over a four-year period.  The QOPI tool, created by ASCO, is a method for measurement of process based practice quality and is available since…


Added by Editorial Team on November 27, 2012 at 6:30pm — No Comments

Multidisciplinary End-of-Life Care Discussion Helps Lowers Utilization of Intensive Care

Advanced life support resources are required for optimal care of patients undergoing curative therapy, but their use in patients with terminal disease does not improve patient outcomes. A study found that a new multidisciplinary team approach for discussion of end-of-life care issues with patients may help decrease the use of intensive care during hospitalizations of patients with advanced cancer, without reducing the proportion of patients who survive to be discharged from the…


Added by Editorial Team on November 27, 2012 at 6:30pm — No Comments

Majority of Preventive Double Mastectomies Occur in Women with Very Low Contralateral Breast Cancer Risk - New Study Reveals Potential Causes

New studies released today reveal important advances in cancer care quality measurement, physician adherence to quality standards, and end-of-life care, while highlighting the overuse of contralateral prophylactic mastectomy (CPM), the -- surgical removal of the pposite, healthy, breast, an option that may reduce the risk of a new cancer developing. The studies were released in a presscast today in advance of American Society of Clinical…


Added by Editorial Team on November 27, 2012 at 6:30pm — No Comments

Private Investment Must Fill the Gap of Increasingly Diminished Source of Federal Biomedical Research Funding

In a commentary to be published in the December 12, 2012 issue of JAMA, The Journal of the American Medical Association (Biomedical Research in an Age of Austerity),  Hamilton Moses III, M.D, an adjunct professor of neurology  of The Johns Hopkins Hospital, and E. Ray Dorsey, M.D., M.B.A., an associate professor of neurology at…


Added by Editorial Team on November 26, 2012 at 9:00am — No Comments

Researchers Identify New Mechanism Through Which Normal Stromal Cells Become Cancer-promoting Stromal Cells

New understanding of molecular changes that convert harmless cells surrounding ovarian cancer cells into cells that promote tumor growth and metastasis provides potential new therapeutic targets for this deadly disease, according to data published in the November 21, 2012 OnlineFirst issue of Cancer Discovery (Cancer Discov; 2(12); 1–9.) , a journal of the American…


Added by Peter Hofland, PhD on November 21, 2012 at 3:00pm — No Comments

New Supportive Care Treatment for Patients with Thrombocytopenia with Chronic Hepatitis C to allow the Initiation and Maintenance of Interferon-based Therapy

The U.S. Food and Drug Administration (FDA) has approved a new indication for eltrombopag (Promacta®/Revolade®; GSK/GlaxoSmithKline), a thrombopoietin receptor agonist.  The new indication approves eltrombopag for the treatment of thrombocytopenia (low blood platelet counts) in patients…


Added by Editorial Team on November 19, 2012 at 5:00pm — No Comments

Interview with John Conway of Cancer Treatment Centers of America

The following interview  with John Conway, Senior Vice President New Market and Business Development, Cancer Treatment Centers of America, originally appeared in Volume 6, Issue 23 of Medical Travel Today, a free online newsletter covering the business side of domestic and international medical travel.

Since 1988, Cancer Treatment Centers of America (CTCA), a national network of fully accredited cancer hospitals,…


Added by Amanda R. Haar on November 19, 2012 at 10:00am — No Comments

European Medicines Agency Offers Positive Opinion Bevacizumab Based Treatment Beyond First Progression in People With Advanced Colorectal

Colorectal cancer is one of the most common cancers in the world, with over 1.2 million new cases diagnosed each year. The disease remains one of the biggest cancer killers in the world responsible for over 600,000 deaths globally each year [1].

Recent studies show that continued use of bevacizumab (Avastin®; Roche/Genentech) -based therapy beyond first progression in metastatic colorectal cancer patients leads to…


Added by Editorial Team on November 16, 2012 at 11:00am — No Comments

U.S. Smoke-Free Laws Spreading -- But More Work Needed to Protect Children From Secondhand Smoke

A report released earlier today by the U.S. Centers for Disease Control and Prevention (CDC) shows that America's largest cities have made enormous progress in implementing smoke-free laws that apply to all workplaces, including restaurants and bars, but there is still much work to do to protect everyone's right to breathe clean air.…


Added by Editorial Team on November 15, 2012 at 3:30pm — No Comments

A New Approach for Anticancer Radiotherapy Could Offer Alternative to Brachytherapy

A promising new approach to treating solid tumors with radiation was highly efficacious and minimally toxic to healthy tissue in a mouse model of cancer, according to data published in November 15, 2012 issue of Cancer Research, a journal of the American Association for Cancer Research.

Patients with solid tumors, including prostate cancer, are often treated using a clinical technique called brachytherapy. Brachytherapy involves the surgical implantation of radioactive…


Added by Peter Hofland, PhD on November 15, 2012 at 11:30am — No Comments

Positive Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma; Results from Phase IV NeoPulse Trial also Encouraging

Melanoma is the most serious form of skin cancer. If it is recognized and treated early, it is almost always curable, but if it is not, the cancer can advance and spread to other parts of the body, where it becomes hard to treat, disfiguring, debilitating and often life-threatening.

While it is not the most common of the skin cancers, it causes the most deaths. The American Cancer Society estimates that at present, about 123,000 new cases of melanoma in the U.S. are diagnosed…


Added by Editorial Team on November 15, 2012 at 3:30am — No Comments

Earlier End of Life Care Discussions are Linked to Less Aggressive Care in Final Days of Life and Increased Use of Hospice Care for Patients

A large population- and health systems-based prospective study reports earlier discussions about end of life (EOL) care preferences are strongly associated with less aggressive care in the last days of life and increased use of hospice care for patients with advanced cancer. The study, published November 13, 2012 issue of the Journal of Clinical Oncology, provides the first-of-its –kind scientific evidence that timing of End of…


Added by Editorial Team on November 13, 2012 at 2:00pm — No Comments

Cancer Genome Project Identifies Abnormal Gene and Provides Insight Into a Tough-to-cure Form of Acute Myeloid Leukemia

Research led by a team of researchers working at the St. Jude Children’s Research Hospital in Memphis, TN and the Washington University Pediatric Cancer Genome Project have identified a fusion gene responsible for nearly 30% of a rare subtype of childhood leukemia with an extremely poor prognosis.

This unique finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic…


Added by Editorial Team on November 12, 2012 at 9:00pm — No Comments

Clinical Data on OncoMed's Anti-Notch2/3 and Demcizumab Programs Released at EORTC-NCI-AACR Symposium

Phase I clinical data on Anti-Notch2/3 was featured earlier this week in an oral plenary session at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. Additional clinical biomarker data were presented in a poster session. Demcizumab (OncoMed Pharmaceuticals, Inc) Phase Ib…


Added by Editorial Team on November 9, 2012 at 11:00pm — No Comments

FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) earlier today designated etirinotecan pegol (NKTR-102; Nektar Therapeutics, San Francisco, CA) as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine (ATC).

Etirinotecan pegol is a unique, targeted topoisomerase I inhibitor based on Nektar's…


Added by Editorial Team on November 7, 2012 at 9:00am — No Comments

Survival and Quality of Life Improve for Prostate Cancer Patients after Proton Therapy

Proton therapy is effective and safe for prostate cancer treatment, according to new research from the University of Florida Proton Therapy Institute. The findings from seven studies were presented Oct. 28-31 in Boston during the American Society for Radiation Oncology (ASTRO) 54th Annual Meeting, the premier scientific conference on radiation…


Added by Peter Hofland, PhD on November 6, 2012 at 6:00pm — No Comments

Multidisciplinary Approach to Screening for and Treating Lung Cancer: Low Dose Computed Tomography Screening Proves Important in Detecting Lung Cancer

November is Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer death for both men and women in the United States. It has a five-year survival rate of only 15 percent. Often, lung cancers grow silently for many years and reach an advanced stage before causing symptoms that lead to diagnosis and treatment. But, there is some good news. Research from the National Cancer…


Added by Editorial Team on November 5, 2012 at 12:30pm — No Comments

First Patient Enrolled in Clinical Trial of Anaplastic Lymphoma Kinase (ALK) Inhibitor TSR-011

Tesaro, an oncology-focused biopharmaceutical company, announced earlier today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has, for the first time, been used in a patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the TGen, the Translational Genomics Research Institute. Virginia…


Added by Peter Hofland, PhD on November 1, 2012 at 11:30am — No Comments

Monthly Archives














Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+